News | September 17, 2024
Merck and Siemens partner on digital transformation technology
MoU signed to drive digital transformation through strategic projects across all three business sectors of Merck
MoU signed to drive digital transformation through strategic projects across all three business sectors of Merck
KEYTRUDA is the first and only immunotherapy-based regimen to show a statistically significant and clinically meaningful improvement in overall survival
India's bio economy has experienced remarkable growth, skyrocketing from US $10 billion in 2014 to over $130 billion in 2024, with projections to reach $300 billion by 2030
The acquisition is based on an enterprise value of Rs. 1,660 crore
The partnership aims to revolutionize Artificial Intelligence in health research with innovative data platform
More than 10 oral and mini-oral presentations span Pfizer’s extensive Oncology portfolio of approved and investigational therapies
The trial met its primary and secondary endpoints demonstrating that administration of a 3-dose regimen of GARDASIL 9
TROPION-Lung01, evaluating AstraZeneca and Daiichi Sankyo’s datopotamab deruxtecan versus chemotherapy, previously met the dual primary endpoint of progression-free survival in the overall trial population
Agreement further expands Aptar Pharma’s leading respiratory portfolio
The collaborations will help curate industry focused courses such as Advanced Certification courses for healthcare professionals in Healthcare Marketing, Healthcare Technology and Specialized Clinical Fellowship Level programs with university accreditation
Subscribe To Our Newsletter & Stay Updated
